SEARCH LISTED COMPANY
ANY AUS OR NZ COMPANY
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
| FROM | TO | |
|---|---|---|
| NEURIZON THERAPEUTICS LIMITED | 15/10/2024 | |
| PHARMAUST LIMITED | 26/11/2004 | 15/10/2024 |
| ECHO TECHNOLOGIES LIMITED | 26/11/2004 |
Level 17, 221 St Georges Terrace, Perth WA 6000
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)name changed to Neurizon Therapeutics Limited | 15/10/2024 |
The suspension of trading in the securities of PharmAust will be lifted from the commencement of trading on Thursday, 18 June 2020, following the release by PAA of an announcement regarding results from SARS-CoV-2 repeat preliminary experiments. | 18/06/2020 |
Monepantel and monepantel sulfone treatment both reduce SARS-CoV-2 (COVID-19) cell-to-cell infectivity in cell culture in a repeat preliminary experimental evaluation. Repeat preliminary experiment data demonstrate suppression of virus infectivity by approximately 95% in cell culture by each drug. Preparations are being made for Phase 1 trial. | 18/06/2020 |
The securities of PharmAust Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of PAA, pending the release of an announcement regarding disclosure of results from the SARS-CoV-2 repeat experiments. | 15/06/2020 |
The suspension of trading in the securities of PharmAust Limited will be lifted immediately following the release by PAA of an announcement regarding disclosure of preliminary results from a pre-clinical trial. | 04/06/2020 |
Monepantel treatment reduces SARS-CoV-2 virus replication in tissue culture (based upon preliminary experiments). Monepantel treatment reduces SARS-CoV-2 cell-to-cell infectivity in tissue culture (based upon preliminary experiments). Promising early data demonstrating suppression of virus by 50-95% requires further confirmation in repeat and more comprehensive studies. | 04/06/2020 |
The securities of PharmAust Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of PAA, pending the release of an announcement regarding disclosure of preliminary results from a pre-clinical trial. | 02/06/2020 |
we understand that on or about this date the company consolidated its shares 1 for 20 | 12/11/2015 |
we understand that on or about this date the company made an in specie distribution of 1 share in Diashi Mining Limited for every 29.24 shares in the company | 22/11/2012 |
shares reinstated to quotation | 18/10/2007 |
lodges 2007 Annual Report and confirms its Announcement of 28 September 2007 that it had been unable to lodge its Full Final Accounts due to the failure of its 40% owned subsidiary, Commonwealth Biotechnologies Inc ("BI"), to provide audited figures in confirmation of its final management accounts | 12/10/2007 |
the application for an interlocutory injunction brought by Chimaera Capital Limited ("himaera") against the Company's current Entitlement Issue was dismissed in the Federal Court yesterday - despite the company requesting information from Commonwealth Biotechnologies Inc ("BI") (of which Dr D'Sylva remains Managing Director) since mid-July 2007 - it has still not received it - this is the only reason for the Company's suspension | 05/10/2007 |
shares suspended from quotation as the company failed to lodge its financial statements | 02/10/2007 |
shares reinstated to quotation | 14/02/2007 |
ADVANCE HEALTHCARE GROUP LIMITED has deferred an equity placement to raise $400,000 until Pharmaust's position in relation to its proposed takeover announced on 5 January 2007 has been clarified | 13/02/2007 |
shares suspended from quotation pending release of an announcement | 09/02/2007 |
name changed from Echo Technologies Limited | 26/11/2004 |
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 10/05/2023 | Sam Wright | 50,000 | $0.082 | $4,100.00 |
| 10/03/2023 | Sam Wright | 85,000 | $0.087 | $7,356.00 |
| 09/01/2023 | Sam Wright | 165,000 | $0.070 | $11,571.00 |
| 13/09/2022 | Sam Wright | 250,000 | $0.075 | $18,750.00 |
| 24/08/2021 | Sam Wright | 500,000 | $0.085 | $42,500.00 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Sergio Duchini | Non Exec Chairman | 17/05/2024 |
| John Clark | Managing Director, Interim CEO | 09/05/2024 |
| Kathryn MacFarlane | Non Exec Director | 17/06/2024 |
| Marcus Hughes | Non Exec Director | 09/05/2024 |
| Stefan Ross | Company Secretary | 24/05/2024 |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|
Date of first appointment, title may have changed.
